Swiss regulator gives green light to first drug to prevent Covid-19
The drug is currently only approved for use to prevent Covid-19 among people who don't receive enough protection from vaccines.
Copyright 2020 The Associated Press. All Rights Reserved
Swissmedic has issued a temporary marketing authorisation for AstraZeneca’s drug Evusheld, making it the first Covid-19 prophylaxis drug approved by the Swiss medical regulator.
This content was published on
2 minutes
Keystone-SDA/jdp
Русский
ru
Швейцарский регулятор одобрил препарат для профилактики Covid-19
This authorisation means that the drug, which is administered as an injection, can now be reimbursed by the federal government or health insurance under certain conditions. Evusheld, which is an antibody combination of Tixagevimab and Cilgavimab, is intended for people 12 years and older who aren’t able to build up sufficient immune defenses against Covid-19 from vaccines.
The federal government has already signed contracts with AstraZeneca’s Swiss subsidiary to procure the Covid-19 drug starting with 5,000 doses, according to Keystone-SDA.
Evusheld is authorised for use for Covid-19 prevention in the United States (emergency use), Japan, the European Union and several other countries.
In the UK, where AstraZeneca has its headquarters, officials recently saidExternal link they will not purchase the drug citing “insufficient data” on the duration of protection it provides against the dominant variant Omicron and its subvariants.
On Friday, the EU extended its recommendation for the drug so that it can also be used as a treatment. Swissmedic is still reviewing Evusheld for use as a treatment. However, Swiss Covid regulations allow for the drug to be used to treat Covid-19 patients under certain conditions as the company’s application is being reviewed.
Other treatments
On Friday, the World Health Organization rescinded recommendations for two Covid-19 antibody therapies, stating that new variants have rendered them obsolete.
The two therapies, sotrovimab and casirivimab-imdevimab, were designed to work by binding to the spike protein of SARS-CoV-2 to neutralise the virus’ ability to infect cells.
GSK and partner Vir Biotechnology’s sotrovimab was pulled off the US market by the Food and Drug Administration (FDA) in April.
In January, the FDA also revised its stance on Casirivimab-imdevimab, which is sold under the name REGEN-COV. It limited the use of the drug sold by Swiss firm Roche and US firm Regeneron to a smaller group of patients, citing that it is less effective against the Omicron variant.
University students in Switzerland join Gaza protest wave
This content was published on
Pro-Palestinian activists occupied university buildings in Lausanne, Geneva and Zurich on Tuesday, widening the protest movement in the Alpine nation.
TradeXBank to resume full operations after Sberbank Switzerland taken off sanctions list
This content was published on
TradeXBank, the former Swiss branch of Russia’s Sberbank, will be able to resume its dollar-denominated activities from the second half of this year.
Geneva decides not to remove controversial memorials
This content was published on
The city of Geneva has presented an action plan regarding a series of controversial local statues and monuments of historical figures linked to racism, colonialism or slavery.
University of Lausanne calls for end to pro-Palestine sit-in
This content was published on
The pro-Palestinian occupation continues at the University of Lausanne (UNIL). On Monday evening, a group of students refused to agree to the deadline set by the rectorate.
Ukraine peace conference should include Russia, says Chinese ambassador
This content was published on
China supports a peace conference on the Ukraine war that would see equal participation of all parties, says Chinese Ambassador to Russia Zhang Hanhui.
This content was published on
A majority of Swiss citizens have open attitudes towards various infertility treatments, including even egg donation, which is currently prohibited.
Reports of Swiss cyber fraud almost doubled in six months
This content was published on
The head of the new Federal Office for Cybersecurity (FOC), Florian Schütz, has presented a new strategy after just over four months in office.
Explainer: How ready is Switzerland for a new wave of Covid-19?
This content was published on
Covid-19 cases are on the rise again, sparking renewed talk of vaccination and a possible return to social distancing in the autumn.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.